Search by Algolia
Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
WK Kellogg CoWK Kellogg Co Reports 8.8% Decline in Net Sales and 78% Drop in Net Income for Quarter Ended June 28, 2025
Backblaze, Inc.Backblaze Reports 16% Revenue Growth in Q2 2025, Launches New Cloud Services
Acadian Asset Management Inc.Acadian Asset Management Reports 16.9% Revenue Growth in Q2 2025
Cabaletta Bio, Inc.Cabaletta Bio Reports $45.1 Million Net Loss in Q2 2025 Amid Increased R&D Expenses
ACHIEVE LIFE SCIENCES, INC.Achieve Life Sciences Reports $25.5 Million Net Loss and Advances Cytisinicline NDA
Athene Holding Ltd.Athene Holding Ltd. Reports Q2 2025 Financial Results with $686M Net Income and $5.36B Revenue
Claritev CorpClaritev Corporation Reports 3.5% Revenue Growth and Significant Operating Income Turnaround in Q2 2025
COLLEGIUM PHARMACEUTICAL, INCCollegium Pharmaceutical Reports 29% Revenue Growth in Q2 2025
Warner Music Group Corp.Warner Music Group Reports 9% Revenue Growth but $16 Million Net Loss in Q3
Akebia Therapeutics, Inc.Akebia Therapeutics Reports 43% Revenue Growth to $62.5 Million for Q2 2025
CONOCOPHILLIPSConocoPhillips Reports Q2 2025 Financial Results with $14.0 Billion in Revenues
PRECISION BIOSCIENCES INCPrecision BioSciences Reports Revenue Decline and Increased Operating Losses in Latest Quarter
Cronos Group Inc.Cronos Group Reports 21% Revenue Growth to $33.5 Million in Q2 2025
Apollo Global Management, Inc.Apollo Global Management Reports Second Quarter 2025 Financial Results
NORTECH SYSTEMS INCNortech Systems Reports Decline in Q2 2025 Financial Performance
Rapport Therapeutics, Inc.Rapport Therapeutics Reports $26.7 Million Net Loss in Q2 2025, Driven by Increased R&D Expenses
Sunrise Realty Trust, Inc.Sunrise Realty Trust Reports 241% Revenue Growth and Increased Net Income in Latest Quarter
Vital Farms, Inc.Vital Farms Reports 25% Revenue Growth to $184.8 Million in Latest 10-Q Filing
REGENXBIO Inc.REGENXBIO Reports Q2 2025 Financial Results with $21.4M Revenue and $70.9M Net Loss
SAB Biotherapeutics, Inc.SAB Biotherapeutics Reports $10.1 Million Net Loss in Q2 2025, Seeks Funding for Clinical Trials
Verano Holdings Corp.Verano Holdings Reports Q2 2025 Financial Results with $202.3M Revenue and Net Loss of $19.2M
Amylyx Pharmaceuticals, Inc.Amylyx Pharmaceuticals Reports $41.4 Million Net Loss in Q2 2025, Focuses on Clinical Pipeline
C4 Therapeutics, Inc.C4 Therapeutics Reports $26M Net Loss in Q2 2025, Revenue Declines
Phathom Pharmaceuticals, Inc.Phathom Pharmaceuticals Reports $39.5M Product Revenue in Q2 2025, Faces $75.8M Net Loss
KALTURA INCKaltura Reports Q2 2025 Financial Results with $44.5M Revenue and Improved Net Loss